The ALN-PCS02 is a SNALP-formulated [106] RNAi therapeutic targeting PCSK9 mRNA, encoding for Convertase Subtilisin/Kexin type 9 (PCSK9) protein for the treatment of hypercholesterolemia. This evidence concerns the gene PCSK9 and Hypercholesterolemia.